Compare EVO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | BWAY |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | Germany | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.6M | 547.7M |
| IPO Year | 2007 | 2011 |
| Metric | EVO | BWAY |
|---|---|---|
| Price | $1.62 | $13.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 143.7K | 75.3K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | $309.69 |
| Revenue Next Year | $10.05 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $11.77 |
| 52 Week High | $4.27 | $26.63 |
| Indicator | EVO | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 36.69 |
| Support Level | $1.50 | $11.90 |
| Resistance Level | $1.97 | $14.83 |
| Average True Range (ATR) | 0.06 | 0.54 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 42.59 | 22.30 |
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.